These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 36211462)

  • 21. Hsa_circ_0017639 regulates cisplatin resistance and tumor growth via acting as a miR-1296-5p molecular sponge and modulating sine oculis homeobox 1 expression in non-small cell lung cancer.
    Chang F; Li J; Sun Q; Wei S; Song Y
    Bioengineered; 2022 Apr; 13(4):8806-8822. PubMed ID: 35287543
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MicroRNA-182 modulates chemosensitivity of human non-small cell lung cancer to cisplatin by targeting PDCD4.
    Ning FL; Wang F; Li ML; Yu ZS; Hao YZ; Chen SS
    Diagn Pathol; 2014 Jul; 9():143. PubMed ID: 25012722
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MiR-192/NKRF axis confers lung cancer cell chemoresistance to cisplatin via the NF-κB pathway.
    Li Y; Zu L; Wu H; Zhang F; Fan Y; Pan H; Du X; Guo F; Zhou Q
    Thorac Cancer; 2022 Feb; 13(3):430-441. PubMed ID: 34953057
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MiR-200b Inhibits Tumor Growth and Chemoresistance via Targeting p70S6K1 in Lung Cancer.
    Jin HF; Wang JF; Song TT; Zhang J; Wang L
    Front Oncol; 2020; 10():643. PubMed ID: 32435616
    [TBL] [Abstract][Full Text] [Related]  

  • 25. LncRNA BLACAT1 is involved in chemoresistance of non‑small cell lung cancer cells by regulating autophagy.
    Huang FX; Chen HJ; Zheng FX; Gao ZY; Sun PF; Peng Q; Liu Y; Deng X; Huang YH; Zhao C; Miao LJ
    Int J Oncol; 2019 Jan; 54(1):339-347. PubMed ID: 30387831
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Exosomal miR-4443 promotes cisplatin resistance in non-small cell lung carcinoma by regulating FSP1 m6A modification-mediated ferroptosis.
    Song Z; Jia G; Ma P; Cang S
    Life Sci; 2021 Jul; 276():119399. PubMed ID: 33781830
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Musashi1 Promotes Non-Small Cell Lung Carcinoma Malignancy and Chemoresistance via Activating the Akt Signaling Pathway.
    Lang Y; Kong X; He C; Wang F; Liu B; Zhang S; Ning J; Zhu K; Xu S
    Cell Physiol Biochem; 2017; 44(2):455-466. PubMed ID: 29141252
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Corrigendum: TKI-Resistant Renal Cancer Secretes Low-Level Exosomal miR-549a to Induce Vascular Permeability and Angiogenesis to Promote Tumor Metastasis.
    Xuan Z; Chen C; Tang W; Ye S; Zheng J; Zhao Y; Shi Z; Zhang L; Sun H; Shao C
    Front Cell Dev Biol; 2021; 9():726535. PubMed ID: 34350190
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Blocking hsa_circ_0074027 suppressed non-small cell lung cancer chemoresistance via the miR-379-5p/IGF1 axis.
    Zheng S; Wang C; Yan H; Du Y
    Bioengineered; 2021 Dec; 12(1):8347-8357. PubMed ID: 34592879
    [TBL] [Abstract][Full Text] [Related]  

  • 30. AKT2 inhibition of cisplatin-induced JNK/p38 and Bax activation by phosphorylation of ASK1: implication of AKT2 in chemoresistance.
    Yuan ZQ; Feldman RI; Sussman GE; Coppola D; Nicosia SV; Cheng JQ
    J Biol Chem; 2003 Jun; 278(26):23432-40. PubMed ID: 12697749
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MicroRNA-155 increases colon cancer chemoresistance to cisplatin by targeting forkhead box O3.
    Gao Y; Liu Z; Ding Z; Hou S; Li J; Jiang K
    Oncol Lett; 2018 Apr; 15(4):4781-4788. PubMed ID: 29552117
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MicroRNA-181a enhances the chemoresistance of human cervical squamous cell carcinoma to cisplatin by targeting PRKCD.
    Chen Y; Ke G; Han D; Liang S; Yang G; Wu X
    Exp Cell Res; 2014 Jan; 320(1):12-20. PubMed ID: 24183997
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Down-regulation of microRNA-26b modulates non-small cell lung cancer cells chemoresistance and migration through the association of PTEN.
    Liang N; Zhou X; Zhao M; Zhao D; Zhu Z; Li S; Yang H
    Acta Biochim Biophys Sin (Shanghai); 2015 Jul; 47(7):530-8. PubMed ID: 26068649
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MiR-192 and miR-662 enhance chemoresistance and invasiveness of squamous cell lung carcinoma.
    Filipska M; Skrzypski M; Czetyrbok K; Stokowy T; Stasiłojć G; Supernat A; Jassem J; Żaczek AJ; Bigda J
    Lung Cancer; 2018 Apr; 118():111-118. PubMed ID: 29571988
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Circ_0004015 silencing represses cisplatin chemoresistance and tumor progression by reducing KLF8 in a miR-198-dependent manner in non-small cell lung cancer.
    Li Y; Yang X; Xiong X
    Genomics; 2022 Mar; 114(2):110294. PubMed ID: 35134495
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oncogenic miR-137 contributes to cisplatin resistance via repressing CASP3 in lung adenocarcinoma.
    Su TJ; Ku WH; Chen HY; Hsu YC; Hong QS; Chang GC; Yu SL; Chen JJ
    Am J Cancer Res; 2016; 6(6):1317-30. PubMed ID: 27429846
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The malignant property of circHIPK2 for angiogenesis and chemoresistance in non-small cell lung cancer.
    Ren M; Song X; Niu J; Tang G; Sun Z; Li Y; Kong F
    Exp Cell Res; 2022 Oct; 419(2):113276. PubMed ID: 35863454
    [TBL] [Abstract][Full Text] [Related]  

  • 38. miR-202 Enhances the Anti-Tumor Effect of Cisplatin on Non-Small Cell Lung Cancer by Targeting the Ras/MAPK Pathway.
    Sun W; Ping W; Tian Y; Zou W; Liu J; Zu Y
    Cell Physiol Biochem; 2018; 51(5):2160-2171. PubMed ID: 30522099
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MiR-200c-3p and miR-485-5p overexpression elevates cisplatin sensitivity and suppresses the malignant phenotypes of non-small cell lung cancer cells through targeting RRM2.
    Liu Y; Zhang Y; Li Q; Xu R; Huang N
    Thorac Cancer; 2022 Jul; 13(13):1974-1985. PubMed ID: 35599447
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Circ_0020123 enhances the cisplatin resistance in non-small cell lung cancer cells partly by sponging miR-140-3p to regulate homeobox B5 (HOXB5).
    Wei D; Zeng J; Rong F; Xu Y; Wei R; Zou C
    Bioengineered; 2022 Mar; 13(3):5126-5140. PubMed ID: 35170372
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.